Ameriprise
CLYM

Ameriprise’s Climb Bio CLYM Stock Holding History

Ameriprise’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.58M Buy
+657,971
New +$6.8M ﹤0.01% 2156
2026
Q1 		– Sell
-139,529
Closed -$558K – 4245
2025
Q4 		$558K Buy
+139,529
New +$335K ﹤0.01% 3581

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ameriprise's CLYM Position: Q2 2026 in Review

Ameriprise opened a new position in Climb Bio (CLYM) in Q2 2026: 657,971 shares worth $8.58M. The stake represents ﹤0.01% of the portfolio and ranks #2156 among its holdings. This is a return to the name: Ameriprise previously reported a position in CLYM as recently as Q4 2025.

Ameriprise first reported a position in CLYM in Q4 2025 and has held it in 2 quarters since. 108 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • Ameriprise held 657,971 shares of Climb Bio worth $8.58M as of Q2 2026.
  • Climb Bio was a new Ameriprise position in Q2 2026.
  • Climb Bio made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #2156 holding.
  • Ameriprise first reported a position in Climb Bio in Q4 2025 and has held it in 2 quarters since.
  • 108 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.